

My Glaucoma Helper

REFERENCES

1. Feehan M., Munger M.A., Cooper D.K., Hess K.T., Durante R., Jones. G.J., Montuoro J. Morrison M.A., Clegg D., Crandall A.S., DeAngelis M.M. Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains. *Journal of Clinical Medicine* 2016 Sep; 5(9) 79. Published online 2016 Sep 7. doi: [10.3390/jcm5090079](https://doi.org/10.3390/jcm5090079)
2. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. *Br. J. Ophthalmol.* 2006;90:262–267. doi: 10.1136/bjo.2005.081224. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
3. Bansal R., Tsai J. Compliance/Adherence to Glaucoma Medications—A Challenge. *J. Curr. Glaucoma Pract.* 2007;1:22–25. doi: 10.5005/jp-journals-10008-1052. [[CrossRef](#)] [[Google Scholar](#)]
4. Alany R.G. Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations. *Curr. Med. Res. Opin.* 2013;29:1187–1189. doi: 10.1185/03007995.2013.818968. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
5. Cate H., Bhattacharya D., Clark A., Holland R., Broadway D.C. Patterns of adherence behaviour for patients with glaucoma. *Eye (Lond.)* 2013;27:545–553. doi: 10.1038/eye.2012.294. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
6. Cate H., Bhattacharya D., Clark A., Fordham R., Holland R. Improving adherence to glaucoma medication: A randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study) *BMC Ophthalmol.* 2014;14:79. doi: 10.1186/1471-2415-14-32. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
7. Rossi G.C.M., Pasinetti G.M., Scudeller L., Radaelli R., Bianchi P.E. Do adherence rates and glaucomatous visual field progression correlate? *Eur. J. Ophthalmol.* 2011;21:410–414. doi: 10.5301/EJO.2010.6112. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
8. Sleath B., Blalock S., Covert D., Stone J.L., Skinner A.C., Muir K., Robin A.L. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. *Ophthalmology.* 2011;118:2398–2402. doi: 10.1016/j.ophtha.2011.05.013. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
9. Lee M.D., Fechtner F.R., Fiscella R.G., Singh K., Stewart W.C. Emerging perspectives on glaucoma: Highlights of a roundtable discussion. *Am. J. Ophthalmol.* 2000;130:S1–S11. doi: 10.1016/S0002-9394(00)00635-8. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
10. Tsai J.C., McClure C.A., Ramos S.E., Schlundt D.G., Pichert J.W. Compliance barriers in glaucoma: A systematic classification. *J. Glaucoma.* 2003;12:393–398. doi: 10.1097/00061198-200310000-00001. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
11. Boland M.V., Chang D.S., Frazier T., Plyler R., Friedman D.S. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: The automated dosing reminder study. *JAMA Ophthalmol.* 2014;132:838–844. doi: 10.1001/jamaophthalmol.2014.856. [[PubMed](#)] [[CrossRef](#)] [[Google Scholar](#)]
12. Duhigg, C. The Power of Habit. Random House, 2012.